Steve works with exceptional scientists and entrepreneurs to help build companies that seek to create vast improvements in patient care and rewarding professional opportunities for employees.
Steve co-led investment and served as both founding CEO and Executive Chairman of Thrive Earlier Detection, a healthcare company advancing a breakthrough blood test for the earlier detection of multiple types of cancer. Thrive was acquired by Exact Sciences in January 2021. Steve also served as Executive Chairman at the molecular technology company ArcherDX, Inc., which was acquired by Invitae in October 2020. Steve also led Section 32’s investments in C2i Genomics, CelsiusTx, and Glympse Bio where he is also Chairman.
Earlier, Steve was President and Chief Operating Officer at Foundation Medicine, which was acquired by Roche in 2018, and also held leadership roles with several biotechnology companies.
Steve holds a PhD degree in political economy and government from Harvard University and a BA degree in economics and political science from Stanford University.
- - C2i Genomics
- - CelsiusTx
- - Glympse Bio
- - ImmuneID